Acquisitions18 Aug 2026, 11:35 am
Piramal Pharma Acquires Additional Stake in Yapan Bio, Becomes Subsidiary
AI Summary
Piramal Pharma Ltd (PPL) has completed the acquisition of an additional 1,46,400 equity shares in Yapan Bio Private Limited for approximately ₹76 crores. This acquisition increases PPL's shareholding in Yapan from 33.33% to 74.00%, transforming Yapan from an associate company into a subsidiary. Yapan, a CDMO specializing in vaccines and biologics, reported revenues of ₹26.91 crores, ₹54.40 crores, and ₹26.34 crores for FY2024, FY2025, and FY2026, respectively. This strategic move integrates Yapan's large molecule capabilities into PPL's offerings, enhancing its ability to develop and scale complex biologic therapies.
Key Highlights
- Piramal Pharma increased stake in Yapan Bio to 74%, making it a subsidiary.
- Acquisition cost approximately ₹76 crores for additional equity shares.
- Yapan Bio is a CDMO focused on vaccines and biologics.
- The move integrates Yapan's capabilities into Piramal Pharma's service offering.
- Yapan's revenue for FY2026 was ₹26.34 crores.
Price Impact
More from PPLPHARMA